TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02797249

Intervention type: OTHER
Group type: OTHER
Intervention: Blank
Description: Routine examination during pregnancy.
Study: NCT04370782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc sulfate 220mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc sulfate 220mg once daily for 5 days
Study: NCT01319565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Arm 1 and Arm 2 - Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mL D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Arm 1 and Arm 2 - Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
Study: NCT04370782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 200 mg once daily for 5 days
Study: NCT02633358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia group
Description: Therapeutic hypothermia
Study: NCT00137852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
Study: NCT00606580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396 topical cream
Description: WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
Study: NCT01319565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Arm 1 and Arm 2 - Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Arm 1 and Arm 2 - Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Arm 1 and Arm 2 - Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
Study: NCT00606580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Alone topical cream
Description: The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle placebo cream
Description: Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
Study: NCT02513238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cell
Description: Stemcells injected into submandibularis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Study: NCT02623868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 50mg 2Tabs.
Description: after taking Standard meal, CKD-519 50mg 2Tabs. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 50mg 2Tabs.
Description: after taking Standard meal, CKD-519 50mg 2Tabs. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 50mg 2Tabs.
Description: after taking Standard meal, CKD-519 50mg 2Tabs. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 50mg 2Tabs.
Description: after taking Standard meal, CKD-519 50mg 2Tabs. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 50mg 2Tabs.
Description: after taking Standard meal, CKD-519 50mg 2Tabs. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 50mg 2Tabs.
Description: after taking Standard meal, CKD-519 50mg 2Tabs. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Tab.
Description: after taking Standard meal, CKD-519 100mg 1Tab. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Tab.
Description: after taking Standard meal, CKD-519 100mg 1Tab. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Tab.
Description: after taking Standard meal, CKD-519 100mg 1Tab. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Tab.
Description: after taking Standard meal, CKD-519 100mg 1Tab. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Tab.
Description: after taking Standard meal, CKD-519 100mg 1Tab. administration.
Study: NCT04325646

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples for serological tests

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples for serological tests

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples, saliva, nasopharyngeal swab for serological tests

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples, saliva, nasopharyngeal swab for serological tests
Study: NCT02623868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Tab.
Description: after taking Standard meal, CKD-519 100mg 1Tab. administration.
Study: NCT04325646

Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples, saliva, nasopharyngeal swab for serological tests
Study: NCT02623868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Cap.
Description: after taking Standard meal, CKD-519 100mg 1Cap. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Cap.
Description: after taking Standard meal, CKD-519 100mg 1Cap. administration.
Study: NCT00089414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol/Drospirenone
Description: Drug administered dependent upon arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol/Drospirenone
Description: Drug administered dependent upon arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol/Drospirenone
Description: Drug administered dependent upon arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDB 2914
Study: NCT02925923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study: NCT02221830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention utilizes a Placebo Camparator
Study: NCT01262131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic therapy protocol A
Description: Application of magnetic fields using the Resonator device Protocol A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic therapy Protocol B
Description: Application of magnetic fields using the Resonator device Protocol B

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo therapy
Description: Application of inactive magnetic fields using the Resonator device
Study: NCT05210673

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS
Description: Preoperative: Preoperative explanation of ERAS. Preoperative medical optimization. Smoking cessation 4-8 weeks before surgery. Nutritional status assessment. Preoperative fasting: 2hours for Clear fluids and water, 6hours for Semi-solid foods and 8 hours for Solid food. Preoperative carbohydrate loading. Pre-anesthetic medication: Avoid long active sedatives. Thromboembolic prophylaxis and Compression stockings Intraoperative: Antimicrobial prophylaxis and skin preparation. Epidural analgesia. Prevention of intraoperative hypothermia. Intraoperative fluid management. Minimize incision. Drain strategy Postoperative: Nasogastric intubation. Early oral intake. Early mobilization. Prevention of postoperative ileus through. Prevention of postoperative nausea and vomiting. Multimodal opioid sparing analgesia. Discharge criteria: Patients have resumed adequate oral intake and normal bowel function, Effective oral pain management and No other clinical or biochemical concerns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non ERAS pathway
Description: standard preoperative preparation intraoperative: combined general and epidural anesthesia postoperative standard care
Study: NCT01403181

Intervention type: DRUG
Intervention: Boceprevir
Description: In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data.
Study: NCT02095977

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fluoroscopy
Description: Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: synchronized high-voltage shock
Description: If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.~For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Holter monitor
Description: Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
Study: NCT00560105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Flute
Description: 8 weeks home use, twice daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acapella
Description: 8 weeks home use, twice daily
Study: NCT01517074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subconjunctival injection
Study: NCT03616626

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Once Daily APBI
Description: Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
Study: NCT00137852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 5 days a week for 5-6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Within 4-8 weeks of chemoradiation therapy
Study: NCT01675011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene® Microspheres

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embosphere®
Study: NCT03504774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cashew or Shrimp Oral Immunotherapy
Description: All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
Study: NCT06128005

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: knowledge translation in nursing for pressure injury care
Description: Pressure injury's knowledge and healing of wound.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: knowledge translation in nursing for pressure injury care
Description: Pressure injury's knowledge and healing of wound.
Study: NCT02220348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Study: NCT04022811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac
Description: the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
Study: NCT03955887

Intervention type: BIOLOGICAL
Intervention: bronchoalveolar lavage fluid (BAL)
Description: Recovery of a 10 mL volume of BAL fluid, performed as part of patient care

Intervention type: BIOLOGICAL
Intervention: bronchoalveolar lavage fluid (BAL)
Description: Recovery of a 10 mL volume of BAL fluid, performed as part of patient care

Intervention type: BIOLOGICAL
Intervention: Venous blood
Description: Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care

Intervention type: BIOLOGICAL
Intervention: Venous blood
Description: Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
Study: NCT02979886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH-a
Description: the hormone reaction to the down regulation of the patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Menopausal Gonadotropins
Description: the effects on the serum LH level of day of HCG
Study: NCT02665234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Tavilermide Ophthalmic Solution
Description: 1% Tavilermide BID Dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Vehicle Ophthalmic Solution
Study: NCT03374514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: instilation of the solution in the middle ear

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile isotonic saline solution
Description: Sterile isotonic saline solution
Study: NCT03535324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROA for optimization
Description: The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: There will be no intervention
Study: NCT01319565

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Arm 2 - Days -3 to -1: Ondansetron 0.15 mg/kg IV x 1 dose pre-TBI. Patients will then receive 2 Gy TBI twice a day for 3 days (total dose 12 Gy) using a linear accelerator in Radiation Oncology.
Study: NCT02623868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Cap.
Description: after taking Standard meal, CKD-519 100mg 1Cap. administration.
Study: NCT01596920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue
Description: Allograft Tissue Cellular Repair Matrix

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non-adherent Dressing
Study: NCT01993550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study: NCT02647502

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
Study: NCT02852915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: Laparoscopic surgery for T4 cancer
Study: NCT02167776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Church-based teaching
Description: In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
Study: NCT01302886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHQ880
Study: NCT02424162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: +2.75 diopters multifocal intraocular lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: +3.25 diopters multifocal intraocular lens
Study: NCT00388609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-646256
Description: Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-646256
Description: Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-646256
Description: Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-646256
Description: Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-646256
Description: Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-646256
Description: Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
Study: NCT05099315

Intervention type: OTHER
Intervention: not applicable, observational study
Description: Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study

Intervention type: OTHER
Intervention: not applicable, observational study
Description: Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study

Intervention type: OTHER
Intervention: not applicable, observational study
Description: Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
Study: NCT02534922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prolanta, a human prolactin receptor antagonist
Description: Daily subcutaneous dosing
Study: NCT04868422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring via wireless internet-based system
Study: NCT02552225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
Study: NCT01085903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg once daily with morning meal for three days administered only to stroke patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline
Description: Observations made at baseline before any intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline
Description: Observations made at baseline before any intervention
Study: NCT03616626

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Twice Daily APBI
Description: Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Irradiation
Description: Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years